跳至主要内容
临床试验/EUCTR2019-004947-65-ES
EUCTR2019-004947-65-ES进行中(未招募)1 期

IMPACT ON THE CLINICAL OUTCOMES AND COST-EFFECTIVENESS OF THE ANTIMICROBIAL THERAPEUTIC MONITORING PROGRAM IN CRITICAL PATIENTS

Santiago Grau Cerrato0 个研究点目标入组 230 人开始时间: 2021年9月1日最近更新:
适应症

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
230

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • 1. Patients of both sexes over 18 years of age
  • 2. Patients admitted to intensive care units with suspected or confirmed bacterial infection of respiratory, urological or abdominal focus
  • 3. Patients being treated with linezolid, meropenem alone or in combination with each other, for at least 72 hours
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 160
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 70

排除标准

  • 1. Pregnant or actively breastfeeding patients.
  • 2. Patients receiving oral linezolid
  • 3. Patients undergoing treatment with any renal replacement therapy or extracorporeal support.

研究者

发起方
Santiago Grau Cerrato

相似试验

IMPACT ON THE CLINICAL OUTCOMES AND... | 临床试验